Company news
KalVista Pharmaceuticals, Inc. news in 2022
KalVista Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
KalVista Pharmaceuticals Announces $58 Million Registered Direct Offering
December 26, 2022
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
December 7, 2022
KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting
November 13, 2022
KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema
October 30, 2022
KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat
October 18, 2022
KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D. as Board Chairman
October 16, 2022
KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop
October 6, 2022
KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema
October 3, 2022
KalVista Pharmaceuticals to Present at the 2022 HAEi Global Leadership Workshop
September 29, 2022
KalVista Pharmaceuticals Reports First Fiscal Quarter Results
September 7, 2022
KalVista Pharmaceuticals Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema
August 22, 2022
KalVista Pharmaceuticals to Present at 1st Annual H.C. Wainwright Hereditary Angioedema Conference
July 18, 2022
KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor Program
July 4, 2022
KalVista Pharmaceuticals to Present Data at the 2022 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
June 22, 2022
KalVista Pharmaceuticals Presents Promising Preclinical Data for Oral Factor XIIa Inhibitor Program
June 7, 2022
KalVista Pharmaceuticals to Present at 13th Annual Jefferies Healthcare Conference
May 31, 2022
KalVista Pharmaceuticals Announces Changes to Board of Directors
May 26, 2022
KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900
May 16, 2022
KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference
April 10, 2022
KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy
March 21, 2022
KalVista Pharmaceuticals Announces Initiation of KVD900 Phase 3 KONFIDENT Clinical Trial
March 6, 2022
KalVista Pharmaceuticals Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief From HAE Attacks in Patients
February 27, 2022
KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
February 2, 2022
KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022
February 1, 2022
KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology
January 23, 2022
Decks in 2022
- HAEi Global Leadership Workshop, Frankfurt, October 6-9, 2022
Conference · 13 slides · October 2022
- EAACI 2022
Conference · 12 slides · Jul 1, 2022